Regenxbio Gene Therapy Placed on FDA Hold
Regenxbio shares dropped after the FDA placed a clinical hold on its gene therapy for Hunter syndrome. Spinal scans identified abnormalities in five study participants. The company plans to review data and await the official letter.
Xurve View
Insights:
Xurve View
REGENXBIO INC placed its experimental gene therapy for a rare inherited disorder on clinical hold on Monday, sending shares down 24% in premarket trading. The action follows spinal scan abnormalities found in five study participants years after treatment.
